13215d7ddb
Issue #46 (Phase A only — Phase B human rating still pending, issue stays open). Adds the data-collection half of the calibration milestone: - scripts/calibration_runner.sh — runs 20 fixed balanced-depth queries across 4 categories (factual, comparative, contradiction-prone, scope-edge), 5 each, capturing per-run logs to docs/stress-tests/M3.3-runs/. - scripts/calibration_collect.py — loads every persisted ResearchResult under ~/.marchwarden/traces/*.result.json and emits a markdown rating worksheet with one row per run. Recovers question text from each trace's start event and category from the run-log filename. - docs/stress-tests/M3.3-rating-worksheet.md — 22 runs (20 calibration + caffeine smoke + M3.2 multi-axis), with empty actual_rating columns for the human-in-the-loop scoring step. - docs/stress-tests/M3.3-runs/*.log — runtime logs from the calibration runner, kept as provenance. Gitignore updated with an exception carving stress-test logs out of the global *.log ignore. Note: M3.1's 4 runs predate #54 (full result persistence) and so are unrecoverable to the worksheet — only post-#54 runs have a result.json sibling. 22 rateable runs is still within the milestone target of 20–30. Phases B (human rating) and C (analysis + rubric + wiki update) follow in a later session. This issue stays open until both are done. Co-Authored-By: Claude Opus 4.6 (1M context) <noreply@anthropic.com>
364 lines
40 KiB
Text
364 lines
40 KiB
Text
Researching: Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing.
|
||
|
||
{"question": "Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing.", "depth": "balanced", "max_iterations": null, "token_budget": null, "event": "ask_started", "logger": "marchwarden.cli", "level": "info", "timestamp": "2026-04-09T01:57:22.951394Z"}
|
||
{"transport": "stdio", "server": "marchwarden-web-researcher", "event": "mcp_server_starting", "logger": "marchwarden.mcp", "level": "info", "timestamp": "2026-04-09T01:57:23.942406Z"}
|
||
{"event": "Processing request of type CallToolRequest", "logger": "mcp.server.lowlevel.server", "level": "info", "timestamp": "2026-04-09T01:57:23.953465Z"}
|
||
{"question": "Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing.", "depth": "balanced", "max_iterations": 5, "token_budget": 20000, "model_id": "claude-sonnet-4-6", "event": "research_started", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.web", "level": "info", "timestamp": "2026-04-09T01:57:24.008304Z"}
|
||
{"step": 1, "decision": "Beginning research: depth=balanced", "question": "Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing.", "context": "", "max_iterations": 5, "token_budget": 20000, "event": "start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:24.008814Z"}
|
||
{"step": 2, "decision": "Starting iteration 1/5", "tokens_so_far": 0, "event": "iteration_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:24.008920Z"}
|
||
{"step": 7, "decision": "Starting iteration 2/5", "tokens_so_far": 1180, "event": "iteration_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:42.087229Z"}
|
||
{"step": 14, "decision": "Starting iteration 3/5", "tokens_so_far": 12270, "event": "iteration_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:47.632253Z"}
|
||
{"step": 21, "decision": "Token budget reached before iteration 4: 25966/20000", "event": "budget_exhausted", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:55.072818Z"}
|
||
{"step": 22, "decision": "Beginning synthesis of gathered evidence", "evidence_count": 24, "iterations_run": 3, "tokens_used": 25966, "event": "synthesis_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:55.072985Z"}
|
||
{"step": 23, "decision": "Parsed synthesis JSON successfully", "duration_ms": 89456, "event": "synthesis_complete", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:59:21.172200Z"}
|
||
{"step": 46, "decision": "Research complete", "confidence": 0.82, "citation_count": 14, "gap_count": 4, "discovery_count": 4, "total_duration_sec": 121.701, "event": "complete", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:59:21.274347Z"}
|
||
{"confidence": 0.82, "citations": 14, "gaps": 4, "discovery_events": 4, "tokens_used": 54153, "iterations_run": 3, "wall_time_sec": 117.15539288520813, "budget_exhausted": true, "event": "research_completed", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.web", "level": "info", "timestamp": "2026-04-09T01:59:21.275590Z"}
|
||
{"error": "[Errno 13] Permission denied: '/home/micro/.marchwarden/costs.jsonl'", "event": "cost_ledger_write_failed", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.web", "level": "warning", "timestamp": "2026-04-09T01:59:21.286942Z"}
|
||
{"event": "Processing request of type ListToolsRequest", "logger": "mcp.server.lowlevel.server", "level": "info", "timestamp": "2026-04-09T01:59:21.531952Z"}
|
||
{"trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "confidence": 0.82, "citations": 14, "tokens_used": 54153, "wall_time_sec": 117.15539288520813, "event": "ask_completed", "logger": "marchwarden.cli", "level": "info", "timestamp": "2026-04-09T01:59:22.766505Z"}
|
||
╭─────────────────────────────────── Answer ───────────────────────────────────╮
|
||
│ CRISPR-Cas9 and CRISPR-Cas12a (formerly Cpf1) are both widely used │
|
||
│ RNA-guided nucleases adapted for genome editing, including in vivo │
|
||
│ applications, but they differ meaningfully in mechanism, structure, PAM │
|
||
│ requirements, cutting pattern, guide RNA architecture, specificity, and │
|
||
│ practical suitability for in vivo delivery. │
|
||
│ │
|
||
│ **Mechanism and DNA Cleavage:** Cas9 (most commonly from Streptococcus │
|
||
│ pyogenes, SpCas9) cleaves both DNA strands at the same position, producing │
|
||
│ blunt-ended double-strand breaks (DSBs) [Source 7]. Cas12a, by contrast, │
|
||
│ introduces staggered cuts that leave 4–5 nucleotide 5′ overhangs [Sources 2, │
|
||
│ 7]. These sticky ends generated by Cas12a may enhance homology-directed │
|
||
│ repair (HDR) efficiency compared to Cas9's blunt ends [Source 2]. │
|
||
│ │
|
||
│ **PAM Sequence:** Cas9 requires an NGG PAM (protospacer adjacent motif) on │
|
||
│ the non-template strand downstream of the target; Cas12a recognizes a T-rich │
|
||
│ PAM (typically TTTV) upstream of the target on the non-template strand │
|
||
│ [Sources 2, 7]. This difference expands the targeting range of Cas12a to │
|
||
│ AT-rich genomic regions where Cas9 is limited. │
|
||
│ │
|
||
│ **Guide RNA:** Cas9 uses a two-component guide (crRNA + tracrRNA, often │
|
||
│ fused as sgRNA), while Cas12a requires only a single crRNA with a short │
|
||
│ direct repeat and processes its own pre-crRNA array, enabling multiplexed │
|
||
│ editing from a single transcript [Sources 2, 7, 13]. │
|
||
│ │
|
||
│ **Specificity and Off-Target Effects:** Kinetic studies show Cas12a exhibits │
|
||
│ greater target specificity than Cas9, attributed to a more stringent DNA │
|
||
│ unwinding mechanism that requires more extensive complementarity before │
|
||
│ cleavage [Source 5]. Cas12a tolerates fewer mismatches between the guide RNA │
|
||
│ and target, resulting in fewer off-target cuts [Sources 2, 5]. │
|
||
│ │
|
||
│ **Editing Efficiency:** In comparative studies using ribonucleoprotein (RNP) │
|
||
│ delivery in rice (OsPDS gene), Cas9 and Cas12a showed different efficiencies │
|
||
│ depending on the target site [Source 1]. In Chlamydomonas reinhardtii, both │
|
||
│ Cas9 and Cas12a RNPs co-delivered with ssODN repair templates achieved │
|
||
│ similar total editing levels of 20–30% [Source 4]. Context and target site │
|
||
│ selection significantly influence which enzyme performs better. │
|
||
│ │
|
||
│ **In Vivo Delivery Considerations:** Both enzymes can be delivered via AAV │
|
||
│ vectors, lipid nanoparticles (LNPs), or as RNPs via electroporation [Sources │
|
||
│ 21, 24]. A critical practical consideration is size: SpCas9 (~4.2 kb coding │
|
||
│ sequence) is near the AAV packaging limit (~4.7–4.8 kb), leaving little room │
|
||
│ for promoter and regulatory elements [Sources 20, 21]. Cas12a variants │
|
||
│ (including engineered compact forms such as EbCas12a) can be packaged │
|
||
│ together with their crRNA within a single AAV vector, which is a significant │
|
||
│ advantage for in vivo delivery [Sources 19, 20, 21]. A miniature Cas12f1 │
|
||
│ variant has also demonstrated efficacy for in vivo retinal gene therapy │
|
||
│ [Source 12]. │
|
||
│ │
|
||
│ **Clinical and Therapeutic Status:** CRISPR-Cas9 is currently the dominant │
|
||
│ nuclease in clinical trials for both ex vivo and in vivo genome editing │
|
||
│ [Sources 8, 11]. Cas12a is gaining traction in therapeutic research, │
|
||
│ particularly where higher specificity or AAV-compatible delivery is required │
|
||
│ [Sources 9, 13, 22]. │
|
||
│ │
|
||
│ **Summary Table:** │
|
||
│ - DNA cut type: Cas9 = blunt; Cas12a = staggered (5′ overhang) │
|
||
│ - PAM: Cas9 = NGG (3′); Cas12a = TTTV (5′) │
|
||
│ - Guide RNA: Cas9 = sgRNA (crRNA+tracrRNA); Cas12a = crRNA only │
|
||
│ - Multiplexing: Cas9 = limited; Cas12a = inherent crRNA array processing │
|
||
│ - Specificity: Cas12a generally higher │
|
||
│ - AAV compatibility: Cas12a variants better suited │
|
||
│ - Clinical use: Cas9 more established; Cas12a emerging │
|
||
╰──────────────────────────────────────────────────────────────────────────────╯
|
||
Citations
|
||
┏━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━┓
|
||
┃ # ┃ Title / Locator ┃ Excerpt ┃ Conf ┃
|
||
┡━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━┩
|
||
│ 1 │ What's the Difference Between │ Cas9...cleaves both strands of │ 0.95 │
|
||
│ │ Cas9 and Cas12a Nucleases? | │ DNA at the same point. This │ │
|
||
│ │ The Scientist │ creates a blunt end │ │
|
||
│ │ https://www.the-scientist.com │ double-stranded break (DSB)... │ │
|
||
│ │ /what-s-the-difference-betwee │ For Cas9 to function, the │ │
|
||
│ │ n-cas9-and-cas12a-nucleases-7 │ protospacer adjacent motif │ │
|
||
│ │ 2481 │ (PAM)—a two to six base pair │ │
|
||
│ │ │ sequence—NGG...must sit │ │
|
||
│ │ │ immediately downstream of the │ │
|
||
│ │ │ target on the opposite strand. │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 2 │ Cas9 versus Cas12a/Cpf1: │ Cas9 and Cas12a have distinct │ 0.97 │
|
||
│ │ Structure-function │ evolutionary origins and │ │
|
||
│ │ comparisons and implications │ exhibit different structural │ │
|
||
│ │ for genome editing - PubMed │ architectures, resulting in │ │
|
||
│ │ https://pubmed.ncbi.nlm.nih.g │ distinct molecular │ │
|
||
│ │ ov/29790280/ │ mechanisms... We discuss │ │
|
||
│ │ │ implications for genome │ │
|
||
│ │ │ editing, and how they may │ │
|
||
│ │ │ influence the choice of Cas9 │ │
|
||
│ │ │ or Cas12a for specific │ │
|
||
│ │ │ applications. │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 3 │ CRISPR-Cas12a More Precise │ Cas12a...is, according to │ 0.90 │
|
||
│ │ Than CRISPR-Cas9 │ scientists at the University │ │
|
||
│ │ https://www.genengnews.com/to │ of Texas at Austin │ │
|
||
│ │ pics/genome-editing/crispr-ca │ (UT-Austin), more effective │ │
|
||
│ │ s12a-more-precise-than-crispr │ and precise... Because Cas │ │
|
||
│ │ -cas9/ │ enzymes occasionally fail to │ │
|
||
│ │ │ cut DNA in the right places, │ │
|
||
│ │ │ or even cut at all, they worry │ │
|
||
│ │ │ developers, who want to modify │ │
|
||
│ │ │ genomes with surgical │ │
|
||
│ │ │ precision, especially in │ │
|
||
│ │ │ therapeutic applications. │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 4 │ Comparison of CRISPR/Cas9 and │ We found that Cas9 and Cas12a │ 0.92 │
|
||
│ │ Cas12a for gene editing in │ RNPs- co-delivered with ssODN │ │
|
||
│ │ Chlamydomonas reinhardtii - │ repair templates- induced │ │
|
||
│ │ ScienceDirect │ similar levels of total │ │
|
||
│ │ https://www.sciencedirect.com │ editing, achieving as much as │ │
|
||
│ │ /science/article/pii/S2211926 │ 20–30 % in all │ │
|
||
│ │ 424004089 │ │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 5 │ Comparison of │ Comparison of │ 0.88 │
|
||
│ │ CRISPR-Cas9/Cas12a │ CRISPR-Cas9/Cas12a │ │
|
||
│ │ Ribonucleoprotein Complexes │ Ribonucleoprotein Complexes │ │
|
||
│ │ for Genome Editing Efficiency │ for Genome Editing Efficiency │ │
|
||
│ │ in the Rice Phytoene │ in the Rice Phytoene │ │
|
||
│ │ Desaturase (OsPDS) Gene - PMC │ Desaturase (OsPDS) Gene │ │
|
||
│ │ https://pmc.ncbi.nlm.nih.gov/ │ │ │
|
||
│ │ articles/PMC6973557/ │ │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 6 │ Current and Prospective │ Current and Prospective │ 0.87 │
|
||
│ │ Applications of CRISPR-Cas12a │ Applications of CRISPR-Cas12a │ │
|
||
│ │ in Pluricellular Organisms - │ in Pluricellular Organisms... │ │
|
||
│ │ PMC │ Mol Biotechnol. 2022 Aug │ │
|
||
│ │ https://pmc.ncbi.nlm.nih.gov/ │ 8;65(2):196–205. doi: │ │
|
||
│ │ articles/PMC9841005/ │ 10.1007/s12033-022-00538-5 │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 7 │ When size matters: A novel │ When size matters: A novel │ 0.90 │
|
||
│ │ compact Cas12a variant for in │ compact Cas12a variant for in │ │
|
||
│ │ vivo genome editing - PMC │ vivo genome editing │ │
|
||
│ │ https://pmc.ncbi.nlm.nih.gov/ │ │ │
|
||
│ │ articles/PMC11253977/ │ │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 8 │ When size matters: A novel │ Altogether, the components of │ 0.91 │
|
||
│ │ compact Cas12a variant for in │ the EbCas12a system are well │ │
|
||
│ │ vivo genome editing - │ below the 4.8-kb packaging │ │
|
||
│ │ ResearchGate │ limit of AAVs, enabling │ │
|
||
│ │ https://www.researchgate.net/ │ successful packaging in the │ │
|
||
│ │ publication/382328745_When_si │ AAV9 │ │
|
||
│ │ ze_matters_A_novel_compact_Ca │ │ │
|
||
│ │ s12a_variant_for_in_vivo_geno │ │ │
|
||
│ │ me_editing │ │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 9 │ Therapeutic In Vivo Gene │ our current results prove that │ 0.88 │
|
||
│ │ Editing Achieved by a │ the miniature Cas12f1 system │ │
|
||
│ │ Hypercompact CRISPR System - │ is a promising gene editing │ │
|
||
│ │ Advanced Science │ tool for retinal gene therapy │ │
|
||
│ │ https://advanced.onlinelibrar │ │ │
|
||
│ │ y.wiley.com/doi/10.1002/advs. │ │ │
|
||
│ │ 202308095 │ │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 10 │ Delivery of CRISPR-Cas tools │ AAV is one of the most │ 0.90 │
|
||
│ │ for in vivo genome editing │ commonly used vector systems │ │
|
||
│ │ therapy: Trends and │ to date, but immunogenicity │ │
|
||
│ │ challenges - ScienceDirect │ against capsid, liver toxicity │ │
|
||
│ │ https://www.sciencedirect.com │ at high dose, and potential │ │
|
||
│ │ /science/article/pii/S0168365 │ genotoxicity caused by │ │
|
||
│ │ 92200027X │ off-target mutagenesis and │ │
|
||
│ │ │ genomic integration remain │ │
|
||
│ │ │ unsolved. │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 11 │ CRISPR-Based Therapeutic │ These Cas proteins are more │ 0.87 │
|
||
│ │ Genome Editing - DSpace@MIT │ compatible with AAV delivery, │ │
|
||
│ │ https://dspace.mit.edu/bitstr │ enabling additional vector │ │
|
||
│ │ eam/handle/1721.1/138388.2/ni │ design options such as │ │
|
||
│ │ hms-1576523.pdf?sequence=4&is │ expanded promoter choices and │ │
|
||
│ │ Allowed=y │ a streamlined delivery. │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 12 │ Revolutionizing in vivo │ Genome editing using the │ 0.85 │
|
||
│ │ therapy with CRISPR/Cas │ CRISPR/Cas system has │ │
|
||
│ │ genome editing: │ revolutionized the field of │ │
|
||
│ │ breakthroughs, opportunities │ genetic engineering, offering │ │
|
||
│ │ and challenges - Frontiers │ unprecedented opportunities │ │
|
||
│ │ https://www.frontiersin.org/j │ for therapeutic applications │ │
|
||
│ │ ournals/genome-editing/articl │ in vivo. │ │
|
||
│ │ es/10.3389/fgeed.2024.1342193 │ │ │
|
||
│ │ /full │ │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 13 │ CRISPR Clinical Trials: A │ CRISPR Clinical Trials: A 2024 │ 0.80 │
|
||
│ │ 2024 Update - Innovative │ Update - Innovative Genomics │ │
|
||
│ │ Genomics Institute │ Institute (IGI) │ │
|
||
│ │ https://innovativegenomics.or │ │ │
|
||
│ │ g/news/crispr-clinical-trials │ │ │
|
||
│ │ -2024/ │ │ │
|
||
├─────┼───────────────────────────────┼────────────────────────────────┼───────┤
|
||
│ 14 │ Alt-R CRISPR-Cas9 vs Cas12a │ The two most popular enzymes │ 0.83 │
|
||
│ │ systems | IDT │ used in CRISPR genome editing │ │
|
||
│ │ https://www.idtdna.com/pages/ │ are Cas9 and Cas12a (Cpf1). │ │
|
||
│ │ technology/crispr/crispr-geno │ These enzymes are highly │ │
|
||
│ │ me-editing/Alt-R-systems │ functional, do not require │ │
|
||
│ │ │ binding to other enzymes as is │ │
|
||
│ │ │ the case for type I CRISPR │ │
|
||
│ │ │ systems, and can be readily │ │
|
||
│ │ │ programmed to target the │ │
|
||
│ │ │ desired genomic DNA site. │ │
|
||
└─────┴───────────────────────────────┴────────────────────────────────┴───────┘
|
||
Gaps
|
||
┏━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
|
||
┃ Category ┃ Topic ┃ Detail ┃
|
||
┡━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┩
|
||
│ source_not_found │ Head-to-head in vivo │ Most comparative studies │
|
||
│ │ efficacy data in mammals │ focused on plants (rice) or │
|
||
│ │ across multiple tissue │ algae (Chlamydomonas) or │
|
||
│ │ types │ used in vitro/ex vivo │
|
||
│ │ │ models. Rigorous │
|
||
│ │ │ side-by-side in vivo │
|
||
│ │ │ mammalian comparisons of │
|
||
│ │ │ Cas9 vs. Cas12a across │
|
||
│ │ │ liver, muscle, CNS, and eye │
|
||
│ │ │ were not identified in │
|
||
│ │ │ available sources. │
|
||
├──────────────────┼─────────────────────────────┼─────────────────────────────┤
|
||
│ source_not_found │ Immunogenicity comparison │ While immunogenicity of │
|
||
│ │ between Cas9 and Cas12a in │ Cas9 is well-documented as │
|
||
│ │ vivo │ a challenge for in vivo │
|
||
│ │ │ delivery, direct │
|
||
│ │ │ comparative immunogenicity │
|
||
│ │ │ data for Cas12a in humans │
|
||
│ │ │ or animal models was not │
|
||
│ │ │ available in the gathered │
|
||
│ │ │ sources. │
|
||
├──────────────────┼─────────────────────────────┼─────────────────────────────┤
|
||
│ source_not_found │ Cas12a clinical trial data │ The IGI clinical trials │
|
||
│ │ │ update and other sources │
|
||
│ │ │ confirm Cas9 dominance in │
|
||
│ │ │ trials but do not provide │
|
||
│ │ │ details on approved or │
|
||
│ │ │ ongoing Cas12a-specific │
|
||
│ │ │ clinical trials. │
|
||
├──────────────────┼─────────────────────────────┼─────────────────────────────┤
|
||
│ source_not_found │ Detailed off-target │ While Cas12a is reported to │
|
||
│ │ profiling comparison in │ be more specific than Cas9 │
|
||
│ │ vivo │ based on kinetic studies, │
|
||
│ │ │ comprehensive in vivo │
|
||
│ │ │ off-target profiling │
|
||
│ │ │ comparing both enzymes │
|
||
│ │ │ systematically across the │
|
||
│ │ │ same targets was not │
|
||
│ │ │ available in the sources. │
|
||
└──────────────────┴─────────────────────────────┴─────────────────────────────┘
|
||
Discovery Events
|
||
┏━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━┓
|
||
┃ ┃ Suggested ┃ ┃ ┃
|
||
┃ Type ┃ Researcher ┃ Query ┃ Reason ┃
|
||
┡━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━┩
|
||
│ related_research │ arxiv │ Cas12a vs Cas9 in │ Head-to-head in │
|
||
│ │ │ vivo editing │ vivo mammalian │
|
||
│ │ │ efficiency │ comparisons are a │
|
||
│ │ │ off-target │ critical gap; │
|
||
│ │ │ mammalian │ preprint servers │
|
||
│ │ │ therapeutic │ may have more │
|
||
│ │ │ comparison 2023 │ recent │
|
||
│ │ │ 2024 │ unpublished data │
|
||
├──────────────────┼───────────────────┼───────────────────┼───────────────────┤
|
||
│ related_research │ database │ CRISPR Cas12a │ Clinical adoption │
|
||
│ │ │ clinical trials │ of Cas12a in vivo │
|
||
│ │ │ ClinicalTrials.go │ is poorly │
|
||
│ │ │ v 2023 2024 │ characterized; a │
|
||
│ │ │ │ ClinicalTrials.go │
|
||
│ │ │ │ v database search │
|
||
│ │ │ │ would clarify │
|
||
│ │ │ │ current status │
|
||
├──────────────────┼───────────────────┼───────────────────┼───────────────────┤
|
||
│ related_research │ arxiv │ Cas12a │ Immunogenicity is │
|
||
│ │ │ immunogenicity │ a key barrier for │
|
||
│ │ │ pre-existing │ in vivo Cas9 │
|
||
│ │ │ immunity in vivo │ delivery; whether │
|
||
│ │ │ gene therapy │ Cas12a poses │
|
||
│ │ │ human │ fewer immune │
|
||
│ │ │ │ challenges is │
|
||
│ │ │ │ clinically │
|
||
│ │ │ │ important but not │
|
||
│ │ │ │ covered in │
|
||
│ │ │ │ sources │
|
||
├──────────────────┼───────────────────┼───────────────────┼───────────────────┤
|
||
│ new_source │ database │ compact Cas12a │ Compact Cas12a │
|
||
│ │ │ EbCas12a AsCas12a │ variants show │
|
||
│ │ │ in vivo liver │ promise for AAV │
|
||
│ │ │ lung CNS │ delivery; recent │
|
||
│ │ │ therapeutic │ therapeutic in │
|
||
│ │ │ editing 2024 │ vivo data would │
|
||
│ │ │ │ strengthen the │
|
||
│ │ │ │ comparison │
|
||
└──────────────────┴───────────────────┴───────────────────┴───────────────────┘
|
||
Open Questions
|
||
┏━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
|
||
┃ Priority ┃ Question ┃ Context ┃
|
||
┡━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┩
|
||
│ high │ Does Cas12a's staggered cutting │ Sources note that staggered │
|
||
│ │ pattern result in meaningfully │ cuts may enhance HDR, but │
|
||
│ │ higher HDR rates than Cas9's │ comparative in vivo HDR │
|
||
│ │ blunt cuts in vivo in │ efficiency data in mammals was │
|
||
│ │ therapeutically relevant cell │ not found in the gathered │
|
||
│ │ types? │ evidence. │
|
||
├──────────┼─────────────────────────────────┼─────────────────────────────────┤
|
||
│ high │ Are there pre-existing │ Immunogenicity is a known │
|
||
│ │ antibodies or T-cell responses │ challenge for Cas9 in vivo; │
|
||
│ │ against Cas12a proteins in │ whether Cas12a, being from │
|
||
│ │ humans that would limit its │ different bacterial origins, │
|
||
│ │ therapeutic use, as has been │ faces similar or lesser immune │
|
||
│ │ documented for SpCas9? │ barriers in human patients is │
|
||
│ │ │ clinically critical. │
|
||
├──────────┼─────────────────────────────────┼─────────────────────────────────┤
|
||
│ high │ Can compact Cas12a variants │ Compact variants fit within AAV │
|
||
│ │ (e.g., EbCas12a, Cas12f) │ packaging limits better than │
|
||
│ │ consistently match or exceed │ Cas9, but their in vivo editing │
|
||
│ │ SpCas9 editing efficiency in │ efficiency relative to SpCas9 │
|
||
│ │ vivo across diverse tissue │ across tissues such as liver, │
|
||
│ │ types? │ muscle, and CNS needs │
|
||
│ │ │ systematic evaluation. │
|
||
├──────────┼─────────────────────────────────┼─────────────────────────────────┤
|
||
│ medium │ How does Cas12a's inherent │ Cas12a can process its own │
|
||
│ │ crRNA array processing and │ pre-crRNA array, enabling │
|
||
│ │ multiplexing capability │ multiplexed targeting from a │
|
||
│ │ translate to in vivo │ single transcript, which is │
|
||
│ │ combinatorial therapeutic │ noted as an advantage but its │
|
||
│ │ strategies compared to │ in vivo therapeutic │
|
||
│ │ Cas9-based multiplex │ exploitation is not │
|
||
│ │ approaches? │ well-characterized in available │
|
||
│ │ │ sources. │
|
||
├──────────┼─────────────────────────────────┼─────────────────────────────────┤
|
||
│ medium │ What is the current status of │ The 2024 CRISPR clinical trials │
|
||
│ │ Cas12a-specific clinical trials │ update from IGI and Frontiers │
|
||
│ │ for in vivo gene therapy, and │ review both highlight Cas9 │
|
||
│ │ how do their safety profiles │ dominance in clinical trials, │
|
||
│ │ compare to Cas9-based trials? │ but Cas12a clinical translation │
|
||
│ │ │ remains poorly documented. │
|
||
└──────────┴─────────────────────────────────┴─────────────────────────────────┘
|
||
╭───────────────────────────────── Confidence ─────────────────────────────────╮
|
||
│ Overall: 0.82 │
|
||
│ Corroborating sources: 14 │
|
||
│ Source authority: high │
|
||
│ Contradiction detected: False │
|
||
│ Query specificity match: 0.85 │
|
||
│ Budget status: spent │
|
||
│ Recency: current │
|
||
╰──────────────────────────────────────────────────────────────────────────────╯
|
||
╭──────────────────────────────────── Cost ────────────────────────────────────╮
|
||
│ Tokens: 54153 │
|
||
│ Iterations: 3 │
|
||
│ Wall time: 117.16s │
|
||
│ Model: claude-sonnet-4-6 │
|
||
╰──────────────────────────────────────────────────────────────────────────────╯
|
||
|
||
trace_id: 9e436db7-fcde-4d0f-a568-c468ae4d419c
|